By Wendy Diller
Beginning in the early 1990s, much of the diagnostics industry stalled, with too many players selling similar instruments that all...
Can Ischemia Technologies Produce the Next Big Cardiac Marker?
In recent years, some creative diagnostic companies have applied pharmaceutical-like marketing techniques to launches of their flagship products. Five-year-old Ischemia Technologies' launch strategy for its cardiac marker, ischemia-modified albumin (IMA) is based on tenets gleaned from these companies' success stories. It is supporting its marker of cardiac ischemia with strong clinical and market development programs, aimed not just at the laboratory but also at clinicians. But the inherent complexities and nuances of the opportunity it addresses are challenging.
More from Innovation
More from In Vivo
• By
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
• By
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
• By
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.